Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand.
Jesse Zanker, Marc Sim, Kate Anderson...
https://pubmed.ncbi.nlm.nih.gov/36349684/Actively Recruiting
Led by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Updated on 2026-02-11
132
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating the effects and mechanisms of Transjugular Intrahepatic Portosystemic Shunt TIPS in improving sarcopenia, a condition of muscle loss common in patients with chronic liver disease and especially cirrhosis. Sarcopenia increases mortality and complications such as hepatic encephalopathy, ascites, and infections. Although TIPS has shown benefits for portal hypertension symptoms and preliminary improvements in muscle mass and function, its exact mechanism is not fully understood. All patients in this study receive TIPS treatment. Participants are divided into two groups based on whether sarcopenia improves after TIPS, determined by CT scans measuring skeletal muscle mass index SMI before and one year after the procedure. Researchers analyze serum levels of fibroblast growth factor 21 FGF21 and monitor changes in nutritional status, muscle strength, and function to explore the relationship between FGF21 and sarcopenia improvement. Participants are followed for one year with blood tests to measure serum FGF21 and imaging to assess muscle mass changes. Muscle strength and walking speed are also monitored. The study evaluates correlations between FGF21 changes and muscle indicators as well as overall survival after TIPS. The study runs from June 2025 to December 2027, with follow-ups to understand the prognosis and guide future treatments for sarcopenia in cirrhosis.
CONDITIONS
Mechanism of TIPS to Improve Sarcopenia
J
Jiacheng Liu Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo Transjugular Intrahepatic Portosystemic Shunt (TIPS) surgical treatment.
1 visit (in-person)
Duration - 1 year
Participants are followed up to assess sarcopenia improvement through imaging, blood samples to test serum FGF21 levels, and assessments of nutritional status, muscle strength, and function indicators.
Regular follow-up visits during 1 year
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jesse Zanker, Marc Sim, Kate Anderson...
https://pubmed.ncbi.nlm.nih.gov/36349684/Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor
The First Affiliated Hospital of Zhengzhou University
Collaborating Sponsor